Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer.

• Tác giả: Hongyan Chen, Ranran Gao, Baolin Liu, Zhihua Liu, Fei Ma, Hongnan Mo, Xiaoying Sun, Binghe Xu, Yuanyuan Zhang, Zemin Zhang, Ning Zhao
• Ngôn ngữ: eng
• Ký hiệu phân loại: 783.19 +Nonets and larger combinations
• Thông tin xuất bản: United States : Cancer cell , 2025
• Bộ sưu tập: NCBI
• ID: 690622

Tóm tắt

Combining immune checkpoint blockade (ICB) with chemotherapy shows promise for treating triple-negative breast cancer (TNBC), though the mechanisms remain incompletely understood. Here, we integrate published and new single-cell RNA sequencing (scRNA-seq) data to investigate the tumor immune microenvironment (TIME) in TNBC patients treated with paclitaxel (PTX), nab-paclitaxel (Nab-PTX), and their combinations with the anti-PD-L1 antibody atezolizumab (ATZ). Compared to ATZ plus PTX, ATZ plus Nab-PTX rewires TCF7